Belantamab for high-risk smoldering myeloma safety and early benefit
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests belantamab mafodotin, a cancer medicine, in people with high-risk smoldering multiple myeloma to see how safe it is and whether it may shrink or control the disease. Because it’s an early-stage study, you would be closely monitored and treated with one main study drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have high-risk smoldering multiple myeloma confirmed by bone marrow results showing at least 10% plasma cells and specific blood and flow-cytometry findings.
- Your health test results fit key safety limits (kidney function, blood counts like neutrophils/hemoglobin/platelets, and liver blood tests).
- Your activity level is good enough (ECOG performance status 0–2).
- You have no “myeloma requiring treatment” signs such as high calcium, certain worsening kidney issues, certain anemia levels, bone damage, or specific high-risk lab/imaging findings.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests belantamab mafodotin in people with multiple myeloma that has come back or is not responding to several prior treatments. It may help shrink the cancer and improve disease control when standard options have already been tried.
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
This trial tests a new drug called Elranatamab for people with a high-risk form of smoldering multiple myeloma (SMM). The goal is to see if the drug can prevent or delay the progression to active multiple myeloma.
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
This Phase 2 trial tests whether alternating doses and schedules of belantamab mafodotin can help people with multiple myeloma that has returned or kept progressing after several prior treatments. You may be eligible if your disease has specific measurable signs and your blood counts and organs are healthy enough for study treatment.
This trial studies a precision approach to treat people with high-risk smoldering myeloma (a condition that can turn into active myeloma). The goal is to see whether the treatment can slow or prevent progression and improve outcomes.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.